source
- Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 millionPfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…
- FDA warns of secondary cancers linked to tazemetostat in follicular lymphoma and epithelioid sarcomaThe FDA issued an alert after the voluntary withdrawal of tazemetostat indications for follicular lymphoma and epithelioid sarcoma, emphasizing the drug's association with secondary primary maligna…